Francis Medical Receives FDA Clearance for Vanquish Water Vapor Ablation System for Localized Prostate Cancer
核心洞察
Francis Medical (搜索), a Maple Grove-based medical technology company, received FDA clearance for its Vanquish Water Vapor Ablation System, a minimally invasive treatment for localized prostate cancer using targeted sterile water vapor.
The VAPOR 2 clinical study demonstrated that 91% of targeted MRI-visible cancer lesions were cleared at 12-month follow-up, with 93% of patients reporting satisfaction with treatment outcomes.
The outpatient procedure takes 30-60 minutes and is designed to minimize side effects like urinary incontinence and erectile dysfunction compared to traditional surgery or radiation therapy.
Maple Grove-based medical technology company Francis Medical (搜索) has received U.S. Food and Drug Administration clearance for its Vanquish Water Vapor Ablation System, marking a significant milestone in minimally invasive prostate cancer treatment. The approval allows the company to begin broader commercial deployment of the technology across the United States after years of clinical development and patient trials.
The Vanquish system is designed to treat localized prostate cancer using targeted sterile water vapor to destroy cancerous tissue while limiting damage to surrounding healthy structures. According to Francis Medical (搜索), the technology specifically targets the approximately 84% of prostate cancer patients whose disease remains localized at the time of diagnosis.
Breakthrough Technology for Targeted Treatment
The Vanquish Water Vapor Ablation System delivers targeted thermal energy directly into cancerous prostate tissue through sterile water vapor administered transurethrally, meaning through the urethra without external incisions. The thermal energy rapidly destroys cancer cells while minimizing collateral injury to nearby nerves and healthy tissue structures.
"I have great hope that it will become, worldwide, the standard of care," said Mike Kujak, President and CEO of Francis Medical (搜索). However, Kujak noted the technology's specific application: "If you have disease everywhere within your prostate, or even outside of your prostate, our technology's probably not the best solution. But most cancer—approximately 84%—is contained within the prostate when a patient shows up. For those patients, we would be a good solution."
The treatment is intended to reduce complications often associated with traditional prostate cancer interventions, including urinary incontinence and erectile dysfunction. The system is being positioned as an alternative between active surveillance and more aggressive interventions such as radical prostatectomy or radiation therapy.
Clinical Trial Results Demonstrate Efficacy
The FDA clearance followed data gathered through the company's VAPOR 2 clinical study, which enrolled 235 men across 26 U.S. clinical sites. The prospective multicenter study focused primarily on men with intermediate-risk localized prostate cancer.
According to company-released findings:
- 91% of targeted MRI-visible cancer lesions were reportedly cleared at the 12-month follow-up stage
- 93% of patients reported satisfaction or high satisfaction with treatment outcomes
- Only 2.7% experienced Grade 2 or higher urinary incontinence complications
Eligibility criteria for the study included men age 50 or older, prostate cancer stage T2c or lower, prostate sizes between 20cc and 80cc, PSA levels of 15 ng/ml or lower, and life expectancy projections exceeding 10 years. Participants continue to be monitored over a five-year follow-up period to evaluate long-term cancer control and durability outcomes, with primary trial completion expected in April 2027.
Outpatient Procedure Design
Company officials describe the Vanquish procedure as a minimally invasive outpatient treatment intended to reduce hospital stays and recovery times. According to Francis Medical (搜索), most procedures are completed within 30 to 60 minutes, patients generally return home the same day, and the treatment avoids external incisions or permanent surgical scars.
The precision of the steam-based therapy offers advantages over traditional methods through targeted treatment that minimizes impact on surrounding areas, reduced side effects with fewer complications compared to invasive surgery or long-term radiation, and efficiency as an outpatient procedure.
Commercial Rollout and Market Expansion
Following FDA clearance, Francis Medical (搜索) has already begun expanding clinical use of the Vanquish system at multiple healthcare centers across the country. Participating medical centers currently include East Valley Urology Center in Mesa, Arizona; The Urology Place in San Antonio, Texas; Pinnacle Surgery Center in Austin, Texas; Minnesota Urology locations in Minnesota; and Chesapeake Regional Surgical Center in Virginia Beach, Virginia.
The company secured approximately $80 million in Series C financing in early 2025 to support clinical trials, regulatory preparation, and commercialization efforts. The funding round helped finance the VAPOR 2 clinical study and scale manufacturing and operational infrastructure ahead of FDA review.
Minnesota MedTech Innovation
Francis Medical (搜索) was founded by medical device entrepreneur Michael Hoey, a longtime Minnesota healthcare innovator known for developing Rezūm therapy, another water vapor-based treatment used for benign prostatic hyperplasia. Hoey previously helped build Maple Grove-based NxThera (搜索) before the company was acquired by Boston Scientific for approximately $406 million.
The company has become part of Minnesota's growing medical technology ecosystem, particularly in the northwest metro region, which has emerged as a major hub for healthcare device innovation. The FDA clearance highlights Minnesota's continued influence in the global medical technology industry, with the Twin Cities region remaining one of the nation's largest medtech clusters.
Future Applications
Although the initial FDA clearance focuses on localized prostate cancer treatment, Francis Medical (搜索) executives have indicated the technology may eventually be adapted for additional cancer applications. The company has publicly identified bladder cancer and kidney cancer as possible future targets for water vapor ablation research and development.